InnovaTV 208

About this trial

This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC). It will test different doses of tisotumab vedotin that are given at different times. It will also compare the side effects and ability to treat tumors of these different doses and schedules. In this study, there will be a safety run-in group of approximately 12 patients that will look at a dose-dense treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In addition to the safety run-in patients, there will be three groups in the study. One group will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).

Patient Profile

A female with histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that is over 18.

Where’s this trial being run?

Cork University Hospital and University Hospital Waterford

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: InnovaTV 208
Number: 10-24
Full Title:

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Principal Investigator: Dr Dearbhaile Collins
Type: Industry Sponsored
Sponsor:

Seagen Inc

Recruitment Started: Global: Yes
Ireland: Yes
Global Recruitment Target: 222
Ireland Recruitment Target: